Welcome to our dedicated page for Werewolf Therapeutics SEC filings (Ticker: HOWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
PFM Health Sciences and related entities report owning 401,110 shares (0.9%) of Werewolf Therapeutics, Inc. (HOWL). The filing states that PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC and Brian D. Grossman may each be deemed to beneficially own 401,110 shares, representing 0.9% of the 44,873,646 shares outstanding used for the calculation. All reporting persons indicate no sole voting or dispositive power and 401,110 shares of shared voting and dispositive power. The statement clarifies the relationships among the entities and includes a certification that the securities were not acquired to influence control.
Werewolf Therapeutics (HOWL) reported continued clinical progress while managing a substantial cash burn. The company held $77.6 million of cash and cash equivalents and
The company advanced its lead programs: WTX-124 has a selected recommended dose and active monotherapy and combination expansion arms with interim data planned for the second half of 2025, and WTX-330 completed Phase 1 and initiated a Phase 1b/2 trial, dosing its first patient. Operating expense reductions versus prior year reflect lower manufacturing and R&D spend for select programs, partially offset by continued clinical and development costs.
Balance sheet and financing items include a $30.0 million term loan carrying a high effective interest cost (reported effective rate ~19.24%) with embedded conversion features and a derivative liability. Management states additional funding will be necessary beyond the 12-month runway to continue development activities.
Werewolf Therapeutics announced that it furnished a press release reporting its financial results for the quarter ended June 30, 2025, and that the press release is provided as Exhibit 99.1. The company also made an updated corporate investor presentation publicly available and furnished it as Exhibit 99.2. The filing specifies that these items are being furnished rather than filed under the Exchange Act and includes a standard cautionary note describing forward-looking statements and associated development, regulatory, and financing risks.
The 8-K does not include the financial figures within its text but notifies investors where the results and presentation are available as exhibits for review.